Reorganization of the Office of Strategic Business Initiatives, 5547-5548 [2024-01708]
Download as PDF
<![CDATA[
5547
Federal Register / Vol. 89, No. 19 / Monday, January 29, 2024 / Notices
EXHIBIT 1—ESTIMATED BURDEN HOURS OVER 3 YEARS—Continued
Number of
respondents
Type of information collection
Number of
responses per
respondent
Hours per
response
Total burden
hours
Telephone ........................................................................................................
Web-based .......................................................................................................
Focus Groups ..................................................................................................
In-person ..........................................................................................................
Automated ** ....................................................................................................
Cognitive Testing *** ........................................................................................
600
3,000
1,500
600
1,500
600
1
1
1
1
1
1
40/60
10/60
2.0
1.0
1.0
1.5
400
500
3,000
600
1,500
900
Totals ........................................................................................................
13,800
na
na
8,900
* May include telephone non-response follow-up in which case the burden will not change.
** May include testing of database software, CAPI software or other automated technologies.
*** May include cognitive interviews for questionnaire or toolkit development, or ‘‘think aloud’’ testing of prototype websites.
EXHIBIT 2—ESTIMATED COST BURDEN OVER 3 YEARS
Number of
respondents
Type of information collection
Total burden
hours
Average
hourly
wage rate *
Total cost
burden
Mail/email .........................................................................................................
Telephone ........................................................................................................
Web-based .......................................................................................................
Focus Groups ..................................................................................................
In-person ..........................................................................................................
Automated ........................................................................................................
Cognitive Testing .............................................................................................
6,000
600
3,000
1,500
600
1,500
600
2,000
400
500
3,000
600
1,500
900
$46.52
46.52
46.52
46.52
46.52
46.52
46.52
$93,040
18,608
23,260
139,560
27,912
69,780
41,868
Totals ........................................................................................................
13,800
8,900
na
412,028
* Bureau of Labor & Statistics on ‘‘Occupational Employment and Wages, May 2022’’ found at the following URL https://www.bls.gov/oes/current/oes_nat.htm#29-0000 for the respondents.
ddrumheller on DSK120RN23PROD with NOTICES1
Request for Comments
In accordance with the Paperwork
Reduction Act, 44 U.S.C. 3501–3520,
comments on AHRQ’s information
collection are requested with regard to
any of the following: (a) whether the
proposed collection of information is
necessary for the proper performance of
AHRQ’s health care research and health
care information dissemination
functions, including whether the
information will have practical utility;
(b) the accuracy of AHRQ’s estimate of
burden (including hours and costs) of
the proposed collection(s) of
information; (c) ways to enhance the
quality, utility and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information upon the
respondents, including the use of
automated collection techniques or
other forms of information technology.
Comments submitted in response to
this notice will be summarized and
included in the Agency’s subsequent
request for OMB approval of the
proposed information collection. All
comments will become a matter of
public record.
VerDate Sep<11>2014
18:33 Jan 26, 2024
Jkt 262001
Dated: January 18, 2024.
Marquita Cullom,
Associate Director.
Prevention, 1600 Clifton Road NE, MS
TW–2, Atlanta, GA 30329. Telephone
770–488–4401; Email: reorgs@cdc.gov.
[FR Doc. 2024–01610 Filed 1–26–24; 8:45 am]
SUPPLEMENTARY INFORMATION:
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Reorganization of the Office of
Strategic Business Initiatives
Centers for Disease Control and
Prevention (CDC), the Department of
Health and Human Services (HHS).
ACTION: Notice.
AGENCY:
CDC has modified its
structure. This notice announces the
reorganization of the Office of Strategic
Business Initiatives (SBI) to transfer its
management of the CDC Gift Review
Panel to the Office of Policy,
Performance, and Evaluation.
DATES: This reorganization was
approved by the Director of CDC on
January 17, 2024.
FOR FURTHER INFORMATION CONTACT:
Kimberly Thurmond, Office of the Chief
Operating Officer, Office of the Director,
Centers for Disease Control and
SUMMARY:
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
Part C
(Centers for Disease Control and
Prevention) of the Statement of
Organization, Functions, and
Delegations of Authority of the
Department of Health and Human
Services (45 FR 67772–76, dated
October 14, 1980, and corrected at 45 FR
69296, October 20, 1980, as amended
most recently at 88 FR 69188–69190,
dated October 5, 2023) is amended to
reflect the reorganization of the Office of
Strategic Business Initiatives within the
Office of the Chief Operating Officer,
Centers for Disease Control and
Prevention. Specifically, the changes are
as follows:
I. Under Part C, Section C–B,
Organization and Functions
• Change all instances of the acronym
SBI to OSBI.
• Delete item (2) of the OSBI (CAJT)
functional statement and insert the
following: (2) strengthens CDC’s
administrative guidance and change
management through agency-wide
conference, policy, delegations of
authority, organization and functions,
and records management.
E:\FR\FM\29JAN1.SGM
29JAN1
5548
Federal Register / Vol. 89, No. 19 / Monday, January 29, 2024 / Notices
• Delete item (5) of the Office of
Business Integrity and Strategic
Management (CAJTB) functional
statement and renumber the remaining
items accordingly.
Delegations of Authority
All delegations and redelegations of
authority made to officials and
employees of affected organizational
components will continue in them or
their successors pending further
redelegation, provided they are
consistent with this reorganization.
(Authority: 44 U.S.C. 3101)
Dia Taylor,
Acting Chief Operating Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2024–01708 Filed 1–26–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifiers: CMS–10858, CMS–
10215 and CMS–10394]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995
(PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information (including each proposed
extension or reinstatement of an existing
collection of information) and to allow
60 days for public comment on the
proposed action. Interested persons are
invited to send comments regarding our
burden estimates or any other aspect of
this collection of information, including
the necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions,
the accuracy of the estimated burden,
ways to enhance the quality, utility, and
clarity of the information to be
collected, and the use of automated
collection techniques or other forms of
information technology to minimize the
information collection burden.
DATES: Comments must be received by
March 29, 2024.
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
18:33 Jan 26, 2024
Jkt 262001
When commenting, please
reference the document identifier or
OMB control number. To be assured
consideration, comments and
recommendations must be submitted in
any one of the following ways:
1. Electronically. You may send your
comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) that are accepting
comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number: ll, Room C4–26–05,
7500 Security Boulevard, Baltimore,
Maryland 21244–1850.
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, please access the CMS PRA
website by copying and pasting the
following web address into your web
browser: https://www.cms.gov/
Regulations-and-Guidance/Legislation/
PaperworkReductionActof1995/PRAListing.
FOR FURTHER INFORMATION CONTACT:
William N. Parham at (410) 786–4669.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
Contents
This notice sets out a summary of the
use and burden associated with the
following information collections. More
detailed information can be found in
each collection’s supporting statement
and associated materials (see
ADDRESSES).
CMS–10858 Rebate Reduction
Requests under Sections 11101 and
11102 of the Inflation Reduction
Act
CMS–10215 Identifying Medicaid
Payment for Physician
Administered Drugs
CMS–10394 Application To Be a
Qualified Entity to Receive
Medicare Data for Performance
Measurement/Reapplication/
Annual Report Worksheet
Under the PRA (44 U.S.C. 3501–
3520), Federal agencies must obtain
approval from the Office of Management
and Budget (OMB) for each collection of
information they conduct or sponsor.
The term ‘‘collection of information’’ is
defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
Section 3506(c)(2)(A) of the PRA
requires Federal agencies to publish a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension or reinstatement of an existing
collection of information, before
submitting the collection to OMB for
approval. To comply with this
requirement, CMS is publishing this
notice.
Information Collection
1. Type of Information Collection
Request: New collection (Request for a
new OMB control number); Title of
Information Collection: Rebate
Reduction Requests under Sections
11101 and 11102 of the Inflation
Reduction Act; Use: Under the authority
in sections 11101 and 11102 of the
Inflation Reduction Act of 2022 (Pub. L.
117–169), the Centers for Medicare &
Medicaid Services (CMS) is
implementing the Medicare Part B Drug
Inflation Rebate Program and the
Medicare Part D Drug Inflation Rebate
Program codified in section 1847A(i)
and section 1860D–14B of the Social
Security Act (‘‘the Act’’), respectively.
In accordance with section 1847A(i) of
the Act, for calendar quarters beginning
January 1, 2023, a manufacturer of a Part
B rebatable drug will owe a rebate, to be
deposited in the Federal Supplementary
Medical Insurance Trust Fund, if the
amount specified in section
1847A(i)(3)(A)(ii)(I) of the Act exceeds
the inflation-adjusted payment amount,
which is calculated as set forth in
section 1847A(i)(3)(C) of the Act. A
‘‘Part B rebatable drug’’ means a singlesource drug or biological product (as
defined section 1847A(c)(6)(D) of the
Act), including a biosimilar biological
product (as defined section
1847A(c)(6)(H) of the Act) but excluding
a qualifying biosimilar biological
product (as defined section
1847A(b)(8)(B)(iii) of the Act), for which
payment is made under Medicare Part
B, except such term shall not include
such a drug or biological product if, as
determined by the Secretary, the average
total allowed charges for such drug or
biological product under Part B for a
year per individual that uses such a
drug or biological product are less than
the applicable threshold; or that is a
vaccine described in subparagraph (A)
or (B) of section 1861(s)(10) of the Act.
In accordance with Section 1860D–14B
of the Act, for each 12-month applicable
period, starting with the applicable
period beginning October 1, 2022, a
manufacturer of a Part D rebatable drug
will owe a rebate, to be deposited in the
Federal Supplementary Medical
Insurance Trust Fund, if the annual
E:\FR\FM\29JAN1.SGM
29JAN1
]]>Agencies
[Federal Register Volume 89, Number 19 (Monday, January 29, 2024)]
[Notices]
[Pages 5547-5548]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-01708]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Reorganization of the Office of Strategic Business Initiatives
AGENCY: Centers for Disease Control and Prevention (CDC), the
Department of Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: CDC has modified its structure. This notice announces the
reorganization of the Office of Strategic Business Initiatives (SBI) to
transfer its management of the CDC Gift Review Panel to the Office of
Policy, Performance, and Evaluation.
DATES: This reorganization was approved by the Director of CDC on
January 17, 2024.
FOR FURTHER INFORMATION CONTACT: Kimberly Thurmond, Office of the Chief
Operating Officer, Office of the Director, Centers for Disease Control
and Prevention, 1600 Clifton Road NE, MS TW-2, Atlanta, GA 30329.
Telephone 770-488-4401; Email: [email protected].
SUPPLEMENTARY INFORMATION: Part C (Centers for Disease Control and
Prevention) of the Statement of Organization, Functions, and
Delegations of Authority of the Department of Health and Human Services
(45 FR 67772-76, dated October 14, 1980, and corrected at 45 FR 69296,
October 20, 1980, as amended most recently at 88 FR 69188-69190, dated
October 5, 2023) is amended to reflect the reorganization of the Office
of Strategic Business Initiatives within the Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
Specifically, the changes are as follows:
I. Under Part C, Section C-B, Organization and Functions
Change all instances of the acronym SBI to OSBI.
Delete item (2) of the OSBI (CAJT) functional statement
and insert the following: (2) strengthens CDC's administrative guidance
and change management through agency-wide conference, policy,
delegations of authority, organization and functions, and records
management.
[[Page 5548]]
Delete item (5) of the Office of Business Integrity and
Strategic Management (CAJTB) functional statement and renumber the
remaining items accordingly.
Delegations of Authority
All delegations and redelegations of authority made to officials
and employees of affected organizational components will continue in
them or their successors pending further redelegation, provided they
are consistent with this reorganization.
(Authority: 44 U.S.C. 3101)
Dia Taylor,
Acting Chief Operating Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024-01708 Filed 1-26-24; 8:45 am]
BILLING CODE 4163-18-P
